Camp4's Q2 Loss Widens, but $50M Placement Pushes Cash Runway to 2028
CAMP has more than doubled off its 52-week low of $1.36 on light trading volume (0.3× avg).
Summary
Camp4 Therapeutics posted a Q2 net loss of $33.5 million, including a $20.9 million non-cash derivative charge, but extended its cash runway to the end of 2028 following the $50.1 million private placement second closing.
Key Events · Earnings and Guidance · CAMP
-
Q2 Net Loss Widens
The net loss for Q2 2026 reached $33.5 million, up from $12.6 million in Q2 2025, driven by a $20.9 million non-cash charge from the derivative tranche liability.
-
Cash Runway Extended to 2028
Cash and equivalents of $86.4 million as of June 30, 2026, plus $46.9 million net proceeds from the August second closing, are expected to fund operations through the end of 2028.
-
Derivative Liability Marked Up
The derivative tranche liability was remeasured to $71.9 million at June 30, 2026, up from $44.8 million at year-end, causing a $27.1 million non-cash loss for the first half.
-
CMP-002 Trial on Track
The Phase 1/2 clinical trial for CMP-002 in SYNGAP1-related disorder is expected to initiate in Q4 2026, following regulatory clearances in Australia and Argentina.
Analysis · CAMP · Life Sciences
The Q2 2026 10-Q reveals a net loss of $33.5 million, largely due to a $20.9 million non-cash charge from the derivative tranche liability tied to the private placement. Thanks to the $50.1 million second closing completed in August, the company now expects its cash to last through the end of 2028—a significant extension from the prior 12-month guidance. The Phase 1/2 trial for CMP-002 in SYNGAP1-related disorder remains on track to start in Q4 2026.
At the time of this filing, CAMP was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $282.4M. The 52-week trading range was $1.36 to $7.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.